Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke

International Journal of Geriatric Psychiatry

Volumn 26, Issue 5, 2011, Pages 495-502

  Yang, Lingli ^a   Zhang, Zhijun ^a   Sun, Dingming ^a   Xu, Zhi ^a   Yuan, Yonggui ^a   Zhang, Xiangrong ^a   Li, Ngjiang ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BDNF; Biomarker; Post stroke depression; tPA

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PROTEIN BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; FEMALE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79953237009     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2552     Document Type: Article

References (47)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. 1993. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35-41.
2. Bachis A, Cruz MI, Nosheny RL, Mocchetti I. 2008. Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex. Neurosci Lett 442: 104-108.
3. Banasiak KJ, Xia Y, Haddad GG. 2000. Mechanisms underlying hypoxia-induced neuronal apoptosis. Prog Neurobiol 62: 215-249. (Pubitemid 30326775)
4. Benarroch EE. 2007. Tissue plasminogen activator: beyond thrombolysis. Neurology 69: 799-802. (Pubitemid 47300938)
5. Benchenane K, Berezowski V, Ali C, et al. 2005. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111: 2241-2249. (Pubitemid 40632441)
6. Candelario-Jalil E. 2009. Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs 10: 644-654.
7. Castren E, Voikar V, Rantamaki T. 2007. Role of neurotrophic factors in depression. Curr Opin Pharmacol 7: 18-21. (Pubitemid 46238033)
8. Chandler WL, Alessi MC, Aillaud MF, et al. 1997. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96: 761-768. (Pubitemid 27329607)
9. Chandler WL, Trimble SL, Loo SC, Mornin D. 1990. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 76: 930-937. (Pubitemid 20295504)
10. Donovan MJ, Miranda RC, Kraemer R, et al. 1995. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Am J Pathol 147: 309-324.
11. Doyle KP, Simon RP, Stenzel-Poore MP. 2008. Mechanisms of ischemic brain damage. Neuropharmacology 55: 310-318.
12. Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatr 59: 1116-1127.
13. Duman RS, Malberg J, Thome J. 1999. Neural plasticity to stress and antidepressant treatment. Biol Psychiatr 46: 1181-1191. (Pubitemid 30114436)
14. Eskandari F, Mistry S, Martinez PE, et al. 2005. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism 54: 918-924. (Pubitemid 40827208)
15. Hachinski VC, Potter P, Merskey H. 1986. Leuko-araiosis: an ancient term for a new problem. Can J Neurol Sci 13: 533-534. (Pubitemid 17212716)
16. Hachinski VC, Potter P, Merskey H. 1987. Leuko-araiosis. Arch Neurol 44: 21-23. (Pubitemid 17087606)
17. Hackett ML, Anderson CS. 2005. Predictors of depression after stroke: a systematic review of observational studies. Stroke 36: 2296-2301. (Pubitemid 41429266)
18. Hama S, Yamashita H, Shigenobu M, et al. 2007. Post-stroke affective or apathetic depression and lesion location: left frontal lobe and bilateral basal ganglia. Eur Arch Psychiatry Clin Neurosci 257: 149-152. (Pubitemid 46599128)
19. Hoff EI, oude Egbrink MG, Heijnen VV, Steinbusch HW, van Oostenbrugge RJ. 2005. In vivo visualization of vascular leakage in photochemically induced cortical infarction. J Neurosci Methods 141: 135-141.
20. Jiménez I, Sobrino T, Rodríguez-Yáñez M, et al. 2009. High serum levels of leptin are associated with post-stroke depression. Psychol Med 39: 1201-1209.
21. Johansson L, Jansson JH, Boman K, et al. 2000. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31: 26-32. (Pubitemid 30035748)
22. Karege F, Perret G, Bondolfi G, et al. 2002a. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 143-148. (Pubitemid 34258493)
23. Karege F, Schwald M, Cisse M. 2002b. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328: 261-264. (Pubitemid 34876661)
24. Kerschensteiner M, Gallmeier E, Behrens L, et al. 1999. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189: 865-870. (Pubitemid 29189691)
25. Kissela B, Broderick J, Woo D, et al. 2001. Greater Cincinnati/Northern Kentucky Stroke Study: volume of first-ever ischemic stroke among blacks in a population-based study. Stroke 32: 1285-1290.
26. Kokaia Z, Andsberg G, Yan Q, Lindvall O. 1998. Rapid alterations of BDNF protein levels in the rat brain after focal ischemia: evidence for increased synthesis and anterograde axonal transport. Exp Neurol 154: 289-301. (Pubitemid 29044202)
27. Kokaia Z, Nawa H, Uchino H, et al. 1996. Regional brain-derived neurotrophic factor mRNA and protein levels following transient forebrain ischemia in the rat. Brain Res Mol Brain Res 38: 139-144. (Pubitemid 26159202)
28. Kokaia Z, Zhao Q, Kokaia M, et al. 1995. Regulation of brain-derived neurotrophic factor gene expression after transient middle cerebral artery occlusion with and without brain damage. Exp Neurol 136: 73-88.
29. Lindgren A, Lindoff C, Norrving B, Åstedt B, Johansson BB. 1996. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 27: 1066-1071. (Pubitemid 26177608)
30. Matrisciano F, Bonaccorso S, Ricciardi A, et al. 2009. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43: 247-254.
31. Nakahashi T, Fujimura H, Altar CA, et al. 2000. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470: 113-117. (Pubitemid 30151080)
32. Nakao N, Kokaia Z, Odin P, Lindvall O. 1995. Protective effects of BDNF and NT-3 but not PDGF against hypoglycemic injury to cultured striatal neurons. Exp Neurol 131: 1-10.
33. Pang PT, Teng HK, Zaitsev E, et al. 2004. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306: 487-491. (Pubitemid 39372449)
34. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. 1998. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561. (Pubitemid 28550429)
35. Petersen AA, Larsen KE, Behr GG, et al. 2001. Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res Bull 56: 331-335. (Pubitemid 33062357)
36. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. 1994. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 343: 940-943. (Pubitemid 24117228)
37. Robinson RG. 2003. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatr 54: 376-387. (Pubitemid 37267864)
38. Schäbitz WR, Steigleder T, Cooper-Kuhn CM, et al. 2007. Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke 38: 2165-2172. (Pubitemid 47012284)
39. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. 2000. Intravenous brain-derived neurotrophic factor reduces infarct size and counter-regulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 31: 2212-2217.
40. Sen S, Duman R, Sanacora G. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatr 64: 527-532.
41. Shimizu E, Hashimoto K, Okamura N, et al. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatr 54: 70-75. (Pubitemid 36776725)
42. Shimohama S, Tamura Y, Akaike A, et al. 1993. Brain-derived neurotrophic factor pretreatment exerts a partially protective effect against glutamate-induced neurotoxicity in cultured rat cortical neurons. Neurosci Lett 164: 55-58. (Pubitemid 24040680)
43. Townend BS, Whyte S, Desborough T, et al. 2007. Longitudinal prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci 14: 429-434. (Pubitemid 46453176)
44. Tsukahara T, Yonekawa Y, Tanaka K, et al. 1994. The role of BDNF in transient forebrain ischemia in the rat brain. Neurosurgery 34: 323-330.
45. Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. 2007. Repairing brain after stroke: a review on post-ischemic neurogenesis. Neurochem Int 50: 1028-1041. (Pubitemid 46962820)
46. Yoshimura R, Mitoma M, Sugita A, et al. 2007. Effects of paroxetine ormilnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatr 31: 1034-1037. (Pubitemid 46824019)
47. Zhang Z, Zhang L, Yepes M, et al. 2002. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106: 740-745. (Pubitemid 34851936)